{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:37:01Z","timestamp":1791265021851,"version":"4.1.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T00:00:00Z","timestamp":1294876800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1001251","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T16:19:50Z","timestamp":1294935590000},"page":"e1001251","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":280,"title":["Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1"],"prefix":"10.1371","volume":"7","author":[{"given":"Iliyana","family":"Mikell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Noah","family":"Sather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros A.","family":"Kalams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Altfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Stamatatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,1,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1128\/JVI.68.8.5142-5155.1994","article-title":"Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.","volume":"68","author":"JP Moore","year":"1994","journal-title":"J Virol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.","volume":"82","author":"GD Tomaras","year":"2008","journal-title":"J Virol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1128\/JVI.00201-06","article-title":"Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.","volume":"80","author":"B Li","year":"2006","journal-title":"J Virol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/JVI.02187-07","article-title":"The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.","volume":"82","author":"PL Moore","year":"2008","journal-title":"J Virol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection.","volume":"100","author":"DD Richman","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1128\/JVI.01482-09","article-title":"Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.","volume":"84","author":"NA Doria-Rose","year":"2010","journal-title":"J Virol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/JVI.02036-08","article-title":"Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.","volume":"83","author":"DN Sather","year":"2009","journal-title":"J Virol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.","volume":"83","author":"MD Simek","year":"2009","journal-title":"J Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nm.1949","article-title":"Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?","volume":"15","author":"L Stamatatos","year":"2009","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1128\/JVI.00093-06","article-title":"Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.","volume":"80","author":"SG Deeks","year":"2006","journal-title":"J Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1128\/JVI.01149-09","article-title":"Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.","volume":"83","author":"A Piantadosi","year":"2009","journal-title":"J Virol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/QAD.0b013e32833243e7","article-title":"Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.","volume":"23","author":"MJ van Gils","year":"2009","journal-title":"AIDS"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1128\/JVI.01762-08","article-title":"Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.","volume":"82","author":"JM Binley","year":"2008","journal-title":"J Virol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/JVI.01992-08","article-title":"Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.","volume":"83","author":"Y Li","year":"2009","journal-title":"J Virol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.virol.2009.10.044","article-title":"Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.","volume":"396","author":"A Nandi","journal-title":"Virology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.","volume":"458","author":"JF Scheid","year":"2009","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/JVI.02631-08","article-title":"In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.","volume":"83","author":"X Shen","year":"2009","journal-title":"J Virol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1128\/JVI.02749-06","article-title":"Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.","volume":"81","author":"AK Dhillon","year":"2007","journal-title":"J Virol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nm1624","article-title":"Broad HIV-1 neutralization mediated by CD4-binding site antibodies.","volume":"13","author":"Y Li","year":"2007","journal-title":"Nat Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1128\/JVI.00154-10","article-title":"Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.","volume":"84","author":"J Pietzsch","year":"2010","journal-title":"J Virol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jmb.2009.04.019","article-title":"Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library.","volume":"389","author":"LM Walker","year":"2009","journal-title":"J Mol Biol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e1001028","DOI":"10.1371\/journal.ppat.1001028","article-title":"A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals.","volume":"6","author":"LM Walker","year":"2010","journal-title":"PLoS Pathog"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood-2003-09-3333","article-title":"Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.","volume":"104","author":"SG Deeks","year":"2004","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.virol.2007.11.009","article-title":"Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope.","volume":"372","author":"A Penn-Nicholson","year":"2008","journal-title":"Virology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1089\/aid.1996.12.911","article-title":"Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding.","volume":"12","author":"JM Binley","year":"1996","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/JVI.79.2.1252-1261.2005","article-title":"Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.","volume":"79","author":"MB Zwick","year":"2005","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"10892","DOI":"10.1128\/JVI.75.22.10892-10905.2001","article-title":"Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.","volume":"75","author":"MB Zwick","year":"2001","journal-title":"J Virol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e8805","DOI":"10.1371\/journal.pone.0008805","article-title":"Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.","volume":"5","author":"D Corti","year":"2010","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/intimm\/9.9.1281","article-title":"Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.","volume":"9","author":"CE Hioe","year":"1997","journal-title":"Int Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1128\/JVI.02588-06","article-title":"An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.","volume":"81","author":"JD Nelson","year":"2007","journal-title":"J Virol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"11265","DOI":"10.1128\/JVI.01359-09","article-title":"Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.","volume":"83","author":"ES Gray","year":"2009","journal-title":"J Virol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"B8","DOI":"10.1016\/j.vaccine.2009.07.085","article-title":"Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects.","volume":"28","author":"DN Sather","year":"2010","journal-title":"Vaccine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1128\/JVI.00239-07","article-title":"Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.","volume":"81","author":"ES Gray","year":"2007","journal-title":"J Virol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"14759","DOI":"10.1073\/pnas.0506927102","article-title":"A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.","volume":"102","author":"MD Miller","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.virol.2008.04.005","article-title":"Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.","volume":"377","author":"JD Nelson","year":"2008","journal-title":"Virology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.","volume":"326","author":"LM Walker","year":"2009","journal-title":"Science"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"10510","DOI":"10.1128\/JVI.00552-10","article-title":"Variable loop glycan dependency of the broad and potent HIV-1 neutralizing antibodies PG9 and PG16.","volume":"84","author":"KJ Doores","year":"2010","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.virol.2007.05.020","article-title":"Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.","volume":"366","author":"NR Derby","year":"2007","journal-title":"Virology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.4049\/jimmunol.150.2.635","article-title":"Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.","volume":"150","author":"MK Gorny","year":"1993","journal-title":"J Immunol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1128\/JVI.76.14.7293-7305.2002","article-title":"The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.","volume":"76","author":"RW Sanders","year":"2002","journal-title":"J Virol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1128\/JVI.76.14.7306-7321.2002","article-title":"The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1\u21922 mannose residues on the outer face of gp120.","volume":"76","author":"CN Scanlan","year":"2002","journal-title":"J Virol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/JVI.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.","volume":"70","author":"A Trkola","year":"1996","journal-title":"J Virol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1086\/651144","article-title":"Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.","volume":"201","author":"Z Euler","year":"2010","journal-title":"J Infect Dis"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.immuni.2008.05.009","article-title":"Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages.","volume":"29","author":"R Nurieva","year":"2008","journal-title":"Immunity"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4049\/jimmunol.173.1.68","article-title":"T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1\/Th2 effector cells that provide help for B cells.","volume":"173","author":"T Chtanova","year":"2004","journal-title":"J Immunol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ni.1877","article-title":"PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells.","volume":"11","author":"K Good-Jacobson","year":"2010","journal-title":"Nat Immunol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1128\/JVI.01583-08","article-title":"Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.","volume":"83","author":"NA Doria-Rose","year":"2009","journal-title":"J Virol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1128\/JVI.79.8.5232-5237.2005","article-title":"Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.","volume":"79","author":"MK Gorny","year":"2005","journal-title":"J Virol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1128\/JVI.02617-09","article-title":"Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian\/human immunodeficiency virus SHIVSF162P4.","volume":"84","author":"JE Robinson","year":"2010","journal-title":"J Virol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"13232","DOI":"10.1128\/JVI.78.23.13232-13252.2004","article-title":"Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.","volume":"78","author":"JM Binley","year":"2004","journal-title":"J Virol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1128\/JVI.77.2.1084-1091.2003","article-title":"Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site.","volume":"77","author":"C Herrera","year":"2003","journal-title":"J Virol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.1175868","article-title":"Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.","volume":"326","author":"L Chen","year":"2009","journal-title":"Science"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1084\/jem.20101176","article-title":"Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.","volume":"207","author":"J Pietzsch","year":"2010","journal-title":"J Exp Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/JVI.01839-06","article-title":"Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.","volume":"81","author":"R Rong","year":"2007","journal-title":"J Virol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1128\/JVI.02554-06","article-title":"Independent evolution of human immunodeficiency virus type 1 env V1\/V2 and V4\/V5 hypervariable regions during chronic infection.","volume":"81","author":"PR Harrington","year":"2007","journal-title":"J Virol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1128\/JVI.00141-06","article-title":"Human immunodeficiency virus type 1 V1\u2013V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.","volume":"80","author":"M Sagar","year":"2006","journal-title":"J Virol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1128\/JVI.00956-06","article-title":"Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian\/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.","volume":"80","author":"NR Derby","year":"2006","journal-title":"J Virol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies.","volume":"79","author":"M Li","year":"2005","journal-title":"J Virol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"11776","DOI":"10.1128\/JVI.01730-06","article-title":"Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.","author":"M Li","year":"2006","journal-title":"J Virol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/088922202753747914","article-title":"HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus.","volume":"18","author":"EM Long","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/QAD.0b013e32805e8727","article-title":"HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.","volume":"21","author":"CA Blish","year":"2007","journal-title":"AIDS"}],"updated-by":[{"DOI":"10.1371\/annotation\/8b3b24b5-d4ed-483a-b233-0a88513ad499","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000}}],"container-title":["PLoS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.ppat.1001251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T17:23:22Z","timestamp":1685899402000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1001251"}},"subtitle":[],"editor":[{"given":"Alexandra","family":"Trkola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,1,13]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1001251","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.8055956.8442054","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,13]]}}}